Literature DB >> 1090438

Dual action of antidepressant drugs (MAO inhibitors) on insulin release.

H Aleyassine, R J Gardiner.   

Abstract

Experiments have been carried out to investigate the role of monoamine oxidase (MAO) in the mechanism of insulin release. Isolated islets and pieces of rat pancreas were incubated in media of high glucose content in the presence of various concentrations of MAO inhibitors. At the end of the incubation, the islet MAO activity and the concentration of insulin released into the medium was measured. The results have shown that: 1. Glucose-mediated insulin release was potentiated by low concentrations of MAO inhibitors, the highest effect being observed at 10 muM. 2. Islet MAO activity was completely abolished in the presence of 10 muM of MAO inhibitors, while at lower concentrations, partial inhibition of enzyme could be achieved. A rise in the concentration of MAO inhibitors was accompanied by a decline in their potentiating effect on insulin secretion. No potentiation was observed at 1 mM concentration, and total inhibition of glucose-mediated insulin release was obtained in the presence of 5-10 mM of MA9 inhibitors. The potentiation of insulin release caused by two of the MAO inhibitors studied was abolished by addition of 1 muM epinephrine into the incubation medium. The basal rate of insulin release was insensitive to low concentrations of MAO inhibitors, but an inhibitory effect was obtained when concentrations were raised to 10 mM. In a comparative study, it was found that MAO activity was greater in liver than in islet tissue, while islets contained three times the activity of exocrine pancreas, consistent with previous findings in islet-cell tumors. The data presented here clearly show that MAO inhibitors are capable of both potentiating and inhibiting insulin release in vitro, depending on their concentrations. It is concluded that the stimulation of glucose-mediated insulin secretion may be related to the MAO inhibitory effects of the drugs, while the inhibition observed at concentrations greater than 1 times 10-3M is due to some other unidentified mechanism.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1090438     DOI: 10.1210/endo-96-3-702

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

1.  Monoamine oxidase in pancreatic islets, exocrine pancreas, and liver from rats. Characterization with clorgyline, deprenyl, pargyline, tranylcypromine, and amezinium.

Authors:  S Lenzen; H Nahrstedt; U Panten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-11       Impact factor: 3.000

2.  Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine.

Authors:  Anthony Raffo; Kolbe Hancock; Teresa Polito; Yuli Xie; Gordon Andan; Piotr Witkowski; Mark Hardy; Pasquale Barba; Caterina Ferrara; Antonella Maffei; Matthew Freeby; Robin Goland; Rudolph L Leibel; Ian R Sweet; Paul E Harris
Journal:  J Endocrinol       Date:  2008-07       Impact factor: 4.286

Review 3.  Drug interactions with oral sulphonylurea hypoglycaemic drugs.

Authors:  J M Hansen; L K Christensen
Journal:  Drugs       Date:  1977-01       Impact factor: 9.546

Review 4.  VMAT2 gene expression and function as it applies to imaging beta-cell mass.

Authors:  Paul E Harris; Caterina Ferrara; Pasquale Barba; Teresa Polito; Matthew Freeby; Antonella Maffei
Journal:  J Mol Med (Berl)       Date:  2007-07-31       Impact factor: 4.599

5.  Serotonin- and Dopamine-Related Gene Expression in db/db Mice Islets and in MIN6 β-Cells Treated with Palmitate and Oleate.

Authors:  L R Cataldo; M L Mizgier; D Busso; P Olmos; J E Galgani; R Valenzuela; D Mezzano; E Aranda; V A Cortés; J L Santos
Journal:  J Diabetes Res       Date:  2016-06-05       Impact factor: 4.011

6.  Metabolic Effects of Oral Phenelzine Treatment on High-Sucrose-Drinking Mice.

Authors:  Christian Carpéné; Saioa Gómez-Zorita; Alice Chaplin; Josep Mercader
Journal:  Int J Mol Sci       Date:  2018-09-25       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.